Lymphomas encompass various lymphoid malignancies, although they are classified and evaluated in a similar manner. Prognostic stratification of lymphomas employs biochemical tests; however, these tests do not offer a viable means of assessing response. We included 108 patients with lymphoma who underwent treatment at the Department of Medical Oncology, Hacettepe University, between January 2015 and December 2017. Patients were grouped into good and poor responders, and changes in biochemical parameters were assessed for their utility in evaluating patient response. We evaluated the proposed scoring system’s effect size using Cramer’s V test. Fifty-seven patients were male, 51 patients were female, and the median age of the patients was 50 years. Twenty-seven patients had HL, 72 patients had B-cell NHL, and 9 patients had T-cell NHL. Fifty-three patients had stage IV, nine patients had stage III, 23 patients had stage II, and 22 patients had stage I disease. Levels of total protein (from 7.12 to 6.79 gr/ dL, p< 0.01), ß2-microglobulin (from 2287 to 2039 ng/mL, p= 0.07), and lactate dehydrogenase (from 297.8 to 230.1 U/L, p< 0.01) decreased in patients with good response, whereas nothing significant was found in patients with poor response. After transforming the parameters, we proposed a 4-point ordinal system comprising total protein, ß2-microglobulin, and lactate dehydrogenase values. Subsequent analysis demonstrated a nearly high effect size (Cramer’s V 0.461) and significance in logistic regression (p< 0.01). Our study presents the first scoring system for response assessment in lymphoma using biochemical tests. Further research is necessary to validate our scoring system. Keywords: Lymphomas, Response evaluation, Biochemistry, Basic scoring
{"title":"Biochemical Response Evaluation on Lymphomas: Proposing a Scoring System","authors":"Efe Cem Erdat","doi":"10.4999/uhod.236946","DOIUrl":"https://doi.org/10.4999/uhod.236946","url":null,"abstract":"Lymphomas encompass various lymphoid malignancies, although they are classified and evaluated in a similar manner. Prognostic stratification of lymphomas employs biochemical tests; however, these tests do not offer a viable means of assessing response. We included 108 patients with lymphoma who underwent treatment at the Department of Medical Oncology, Hacettepe University, between January 2015 and December 2017. Patients were grouped into good and poor responders, and changes in biochemical parameters were assessed for their utility in evaluating patient response. We evaluated the proposed scoring system’s effect size using Cramer’s V test. Fifty-seven patients were male, 51 patients were female, and the median age of the patients was 50 years. Twenty-seven patients had HL, 72 patients had B-cell NHL, and 9 patients had T-cell NHL. Fifty-three patients had stage IV, nine patients had stage III, 23 patients had stage II, and 22 patients had stage I disease. Levels of total protein (from 7.12 to 6.79 gr/ dL, p< 0.01), ß2-microglobulin (from 2287 to 2039 ng/mL, p= 0.07), and lactate dehydrogenase (from 297.8 to 230.1 U/L, p< 0.01) decreased in patients with good response, whereas nothing significant was found in patients with poor response. After transforming the parameters, we proposed a 4-point ordinal system comprising total protein, ß2-microglobulin, and lactate dehydrogenase values. Subsequent analysis demonstrated a nearly high effect size (Cramer’s V 0.461) and significance in logistic regression (p< 0.01). Our study presents the first scoring system for response assessment in lymphoma using biochemical tests. Further research is necessary to validate our scoring system. Keywords: Lymphomas, Response evaluation, Biochemistry, Basic scoring","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136369649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The classification of central nervous system (CNS) tumors by the 2021 World Health Organization (WHO) has led to significant changes in tumor taxonomy. One of the most significant changes is that isocitrate dehydrogenase (IDH) mutant forms of glioblastoma multiforme (GBM) have been differentiated into separate entities, no longer allowing entries to be classified as not otherwise specified (NOS). As a result, this entity only comprises the most aggressive adult-type tumors and established prognostic factors no longer apply. Glioblastoma (GBM) IDH-wildtype CNS WHO grade 4 typically presents necrosis and/or microvascular proliferation and molecular alterations. Herein, we aimed to classify glioblastoma cases to establish a patient survival pattern based on age, gender, the number of masses, tumor location, functional localization, presence of shift, the volume of edema and necrosis, extent of surgery, radiotherapychemotherapy protocol, and isocitrate dehydrogenase (IDH) presence, affecting overall survival were determined retrospectively. A total of 433 patients >20 years old with primary GBM were treated in a single institution between 1996 and 2019. The median survival was 9±0.62 [95% CI 7.78-10.21] months and the survival rate after diagnosis was 39.4% in 1st year, 17% in 2nd year, and 5% in 3rd year. Statistically, age, tumor location, edema, and necrosis were indicated as independent preoperative predictors of prognosis, and younger age at diagnosis, the left temporal and the right occipital location, maximal tumor resection, and administration of temozolomide adjuvant chemotherapy were revealed favorable prognostic factors. Keywords: Glioblastoma, Overall survival, Prognosis, Surgery
2021年世界卫生组织(WHO)对中枢神经系统(CNS)肿瘤的分类导致了肿瘤分类学的重大变化。最重要的变化之一是异柠檬酸脱氢酶(IDH)突变形式的多形性胶质母细胞瘤(GBM)已被分化为单独的实体，不再允许将其归类为未另行指定(NOS)。因此，该实体仅包括最具侵袭性的成人型肿瘤，既定的预后因素不再适用。胶质母细胞瘤(GBM) idh野生型CNS WHO 4级典型表现为坏死和/或微血管增生和分子改变。在此，我们的目的是对胶质母细胞瘤病例进行分类，建立患者的生存模式，基于年龄、性别、肿块数量、肿瘤位置、功能定位、移位的存在、水肿和坏死的体积、手术程度、放化疗方案和异柠檬酸脱氢酶(IDH)的存在，回顾性地确定影响总生存的因素。1996年至2019年期间，共有433名20岁原发性GBM患者在同一家机构接受了治疗。中位生存期为9±0.62 [95% CI 7.78 ~ 10.21]个月，诊断后1年生存率为39.4%，2年生存率为17%，3年生存率为5%。统计学上，年龄、肿瘤位置、水肿和坏死被认为是术前预后的独立预测因素，诊断时年龄较小、左颞部和右枕部位置、肿瘤最大切除和替莫唑胺辅助化疗是预后的有利因素。关键词:胶质母细胞瘤，总生存率，预后，手术
{"title":"The Prognostic Value of the Treatment and Outcome in Patients with Glioblastoma: A Retrospective Cohort Study","authors":"Ugur Yazar","doi":"10.4999/uhod.236721","DOIUrl":"https://doi.org/10.4999/uhod.236721","url":null,"abstract":"The classification of central nervous system (CNS) tumors by the 2021 World Health Organization (WHO) has led to significant changes in tumor taxonomy. One of the most significant changes is that isocitrate dehydrogenase (IDH) mutant forms of glioblastoma multiforme (GBM) have been differentiated into separate entities, no longer allowing entries to be classified as not otherwise specified (NOS). As a result, this entity only comprises the most aggressive adult-type tumors and established prognostic factors no longer apply. Glioblastoma (GBM) IDH-wildtype CNS WHO grade 4 typically presents necrosis and/or microvascular proliferation and molecular alterations. Herein, we aimed to classify glioblastoma cases to establish a patient survival pattern based on age, gender, the number of masses, tumor location, functional localization, presence of shift, the volume of edema and necrosis, extent of surgery, radiotherapychemotherapy protocol, and isocitrate dehydrogenase (IDH) presence, affecting overall survival were determined retrospectively. A total of 433 patients >20 years old with primary GBM were treated in a single institution between 1996 and 2019. The median survival was 9±0.62 [95% CI 7.78-10.21] months and the survival rate after diagnosis was 39.4% in 1st year, 17% in 2nd year, and 5% in 3rd year. Statistically, age, tumor location, edema, and necrosis were indicated as independent preoperative predictors of prognosis, and younger age at diagnosis, the left temporal and the right occipital location, maximal tumor resection, and administration of temozolomide adjuvant chemotherapy were revealed favorable prognostic factors. Keywords: Glioblastoma, Overall survival, Prognosis, Surgery","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"240 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136369650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dosimetric Comparison of Between Multileaf and Fixed Cone Collimator Plans with Cyberknife-M6 in the Benign Skull Base Tumors","authors":"Candan Demiroz Abakay","doi":"10.4999/uhod.236792","DOIUrl":"https://doi.org/10.4999/uhod.236792","url":null,"abstract":"","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136369651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Colorectal cancer is one of the most common types of cancer. CRNDE is a novel-defined lncRNA. We evaluated the possibility of using CRDNE circulating lncRNA as a noninvasive biomarker. Also, we examined the effect of circulating CRNDE lncRNA on the pathogenesis of CRC and its association with the KRAS, NRAS, and BRAF somatic variants commonly observed in CRC. In this study, we enrolled plasma and FFPE tissue samples of 50 advanced CRC patients and plasma samples of 31 individuals in the control group of similar ages. Then, we performed plasma extraction, total RNA isolation, cDNA synthesis, and circulating lncRNA expression analysis, respectively. Also, we carried out KRAS, NRAS, and BRAF somatic variant analysis from FFPE tissues. Our results showed that the expression level of CRNDE (p= 0.002) were significantly upregulated in the CRC when it was compared to with the control group. The calculated area under the curve of the receiver operating characteristic was 0.70. We found a statistically significant difference between the KRAS somatic variants and the circulating CRNDE lncRNA (p= 0.031). This study demonstrated that CRNDE circulating lncRNAs may be used as a potential non-invasive biomarker in CRC. In our study, it was determined that there is a significant relationship between the frequently observed KRAS somatic variants and CRNDE in advanced-stage CRC cases. To the best of our knowledge, this is the first study to show the association of CRNDE circulating lncRNA with advanced CRC. Moreover, it is the first study to show a relationship between the KRAS somatic variants between circulating CRNDE lncRNA in advanced CRC. Keywords: CRNDE, Circulating lncRNA, KRAS, CRC, RT-PCR
{"title":"Evaluation of the Association Between CRNDE Plasma Expression Level, KRAS, NRAS, and BRAF Variants in Patients with advanced CRC","authors":"Serap Arslan","doi":"10.4999/uhod.236797","DOIUrl":"https://doi.org/10.4999/uhod.236797","url":null,"abstract":"Colorectal cancer is one of the most common types of cancer. CRNDE is a novel-defined lncRNA. We evaluated the possibility of using CRDNE circulating lncRNA as a noninvasive biomarker. Also, we examined the effect of circulating CRNDE lncRNA on the pathogenesis of CRC and its association with the KRAS, NRAS, and BRAF somatic variants commonly observed in CRC. In this study, we enrolled plasma and FFPE tissue samples of 50 advanced CRC patients and plasma samples of 31 individuals in the control group of similar ages. Then, we performed plasma extraction, total RNA isolation, cDNA synthesis, and circulating lncRNA expression analysis, respectively. Also, we carried out KRAS, NRAS, and BRAF somatic variant analysis from FFPE tissues. Our results showed that the expression level of CRNDE (p= 0.002) were significantly upregulated in the CRC when it was compared to with the control group. The calculated area under the curve of the receiver operating characteristic was 0.70. We found a statistically significant difference between the KRAS somatic variants and the circulating CRNDE lncRNA (p= 0.031). This study demonstrated that CRNDE circulating lncRNAs may be used as a potential non-invasive biomarker in CRC. In our study, it was determined that there is a significant relationship between the frequently observed KRAS somatic variants and CRNDE in advanced-stage CRC cases. To the best of our knowledge, this is the first study to show the association of CRNDE circulating lncRNA with advanced CRC. Moreover, it is the first study to show a relationship between the KRAS somatic variants between circulating CRNDE lncRNA in advanced CRC. Keywords: CRNDE, Circulating lncRNA, KRAS, CRC, RT-PCR","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136369648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ozge Ulas BABACAN1, Zekiye HASBEK2, Mukaddes YILMAZ3, Hatice OZER4, Hilmi ATASEVEN5 1Bitlis State Hospital, Department of Nuclear Medicine, Bitlis 2Cumhuriyet University Faculty of Medicine, Department of Nuclear Medicine 3Cumhuriyet University Faculty of Medicine, Department of Oncology 4Cumhuriyet University Faculty of Medicine, Department of Pathology 5Cumhuriyet University Faculty of Medicine, Department of Gastroenterology Keywords: HDAC, HDACI, 18F-FDG PET/CT, Gastric cancer Histon Deacetylases (HDACs) exert a pro-oncogenic effect by keeping genes that cause differentiation, apoptosis, and cell cycle arrest in a transcriptionally quiescent state. Moreover to achieve our aim, we investigated the relationship between the patients’ HDAC protein expression rates and their prognosis. In no patients, tumors were located in the cardia and corpus. While the median HDAC1 protein score was 3.5 in the early stage patients, it was 8 in the advanced stage (stage 1-2) patients, and 12 in the metastatic stage (stage 4) patients. There was a significant correlation between HDAC protein positivity and tumor localization (p= 0.030). Significant correlation was observed between histopathological stages and median HDAC1 protein scores. (p= 0.021). The HDAC1 protein score increased as the patients’ stage progressed. Given the relationship between HDAC1 proteins and the survival of the patients, the 2-year survival rate was high in HDAC1 positive patients; however, it was not statistically significant. According to the results of our study, in HDAC1-positive gastric cancer patients, there was no significant relationship between SUVmax showing tumor metabolism in 18F-FDG PET/CT.
{"title":"Relationship between Histone Deacetylase (HDAC) Overexpression and 18F-FDG PET/CT Parameters in Patients with Gastric Cancer, and Prognostic Importance of HDAC Overexpression","authors":"Ozge Ulas Babacan","doi":"10.4999/uhod.236787","DOIUrl":"https://doi.org/10.4999/uhod.236787","url":null,"abstract":"Ozge Ulas BABACAN1, Zekiye HASBEK2, Mukaddes YILMAZ3, Hatice OZER4, Hilmi ATASEVEN5 1Bitlis State Hospital, Department of Nuclear Medicine, Bitlis 2Cumhuriyet University Faculty of Medicine, Department of Nuclear Medicine 3Cumhuriyet University Faculty of Medicine, Department of Oncology 4Cumhuriyet University Faculty of Medicine, Department of Pathology 5Cumhuriyet University Faculty of Medicine, Department of Gastroenterology Keywords: HDAC, HDACI, 18F-FDG PET/CT, Gastric cancer Histon Deacetylases (HDACs) exert a pro-oncogenic effect by keeping genes that cause differentiation, apoptosis, and cell cycle arrest in a transcriptionally quiescent state. Moreover to achieve our aim, we investigated the relationship between the patients’ HDAC protein expression rates and their prognosis. In no patients, tumors were located in the cardia and corpus. While the median HDAC1 protein score was 3.5 in the early stage patients, it was 8 in the advanced stage (stage 1-2) patients, and 12 in the metastatic stage (stage 4) patients. There was a significant correlation between HDAC protein positivity and tumor localization (p= 0.030). Significant correlation was observed between histopathological stages and median HDAC1 protein scores. (p= 0.021). The HDAC1 protein score increased as the patients’ stage progressed. Given the relationship between HDAC1 proteins and the survival of the patients, the 2-year survival rate was high in HDAC1 positive patients; however, it was not statistically significant. According to the results of our study, in HDAC1-positive gastric cancer patients, there was no significant relationship between SUVmax showing tumor metabolism in 18F-FDG PET/CT.","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136369645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Merve AYIK TURK1, Berna KOMURCUOGLU2, Ahmet YANARTAS3, Ozgur BATUM2, Yunus TURK4, Mehmet Ufuk YILMAZ5 1Izmir Bozyaka Training and Research Hospital, Department of Pulmonology, İzmir 2Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Department of Pulmonology, İzmir 3Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Department of Nuclear Medicine, İzmir 4Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Department of Thoracic Surgery, İzmir 5Medicana Health Groups, Department of Pulmonology, İzmir Keywords: Small cell lung cancer, Prognostic factors, Limited stage, Bone marrow FDG uptake Small cell lung cancer (SCLC) is a malignancy from the neuroendocrine tumor family, which has a poor prognosis and presents with metastases at the time of the diagnosis. The present study investigated the relationship between bone marrow fluorodeoxy-D-glucose (FDG) uptake and survival to evaluate prognosis in limited-stage SCLC. This single-center retrospective study examined a total of 220 patients diagnosed with limited-stage SCLC between January 2010 and June 2019. Bone marrow FDG uptake, serum inflammatory markers, and other factors used to determine the prognosis, as well as overall survival (OS) and progression-free survival (PFS), were recorded and retrospectively analyzed. Within physiological limits, bone marrow standardized uptake value (SUV) mean of > 1.95 was identified as a good prognostic factor for PFS (p= 0.03). The multivariate analysis of OS and PFS revealed that the Eastern Cooperative Oncology Group (ECOG) performance scale (p= 0.001) was a common independent prognostic factor. Stages of the disease, albumin levels and bone marrow-to-liver ratio (BLR) [one of the positron emission tomography/computed tomography (PET/CT) parameters] of < 0.8 were prognostic factors for OS. The bone marrow SUV mean was positively correlated with the primary tumor SUV max and SUV mean. The bone marrow SUV mean is a parameter that can be used to predict PFS in limited-stage SCLC. For OS, in turn, the BLR was identified as an independent factor.
Merve AYIK TURK1, Berna KOMURCUOGLU2, Ahmet YANARTAS3, Ozgur BATUM2, Yunus TURK4, Mehmet Ufuk YILMAZ5 1Izmir Bozyaka培训与研究医院肺病科，İzmir 2中山七胸外科培训研究医院，肺科，İzmir七科胸外科培训研究医院，核医学部，İzmir七胸外科培训与研究医院胸外科İzmir 5Medicana健康集团肺内科İzmir关键词:小细胞肺癌，预后因素，局限期，骨髓FDG摄取小细胞肺癌(Small cell lung cancer, SCLC)是一种神经内分泌肿瘤家族的恶性肿瘤，预后较差，诊断时伴有转移。本研究探讨骨髓氟脱氧- d-葡萄糖(FDG)摄取与生存的关系，以评估有限期SCLC的预后。这项单中心回顾性研究调查了2010年1月至2019年6月期间诊断为有限期SCLC的220例患者。记录并回顾性分析骨髓FDG摄取、血清炎症标志物和其他决定预后的因素，以及总生存期(OS)和无进展生存期(PFS)。在生理限度内，骨髓标准化摄取值(SUV)平均值为;1.95被认为是PFS的良好预后因素(p= 0.03)。OS和PFS的多变量分析显示，Eastern Cooperative Oncology Group (ECOG)绩效量表(p= 0.001)是常见的独立预后因素。疾病分期、白蛋白水平和骨髓肝比(BLR)[正电子发射断层扫描/计算机断层扫描(PET/CT)参数之一];0.8个是OS的预后因素。骨髓SUV均值与原发肿瘤SUV max、SUV均值呈正相关。骨髓SUV均值是预测有限期SCLC患者PFS的一个参数。对于OS，反过来，BLR被确定为一个独立的因素。
{"title":"Prognostic Value of 18F-Fluorodeoxyglucose Uptake of Bone Marrow on PET/CT in Patients with Limited Disease Small Cell Lung Cancer","authors":"Merve Ayik Turk","doi":"10.4999/uhod.236821","DOIUrl":"https://doi.org/10.4999/uhod.236821","url":null,"abstract":"Merve AYIK TURK1, Berna KOMURCUOGLU2, Ahmet YANARTAS3, Ozgur BATUM2, Yunus TURK4, Mehmet Ufuk YILMAZ5 1Izmir Bozyaka Training and Research Hospital, Department of Pulmonology, İzmir 2Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Department of Pulmonology, İzmir 3Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Department of Nuclear Medicine, İzmir 4Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Department of Thoracic Surgery, İzmir 5Medicana Health Groups, Department of Pulmonology, İzmir Keywords: Small cell lung cancer, Prognostic factors, Limited stage, Bone marrow FDG uptake Small cell lung cancer (SCLC) is a malignancy from the neuroendocrine tumor family, which has a poor prognosis and presents with metastases at the time of the diagnosis. The present study investigated the relationship between bone marrow fluorodeoxy-D-glucose (FDG) uptake and survival to evaluate prognosis in limited-stage SCLC. This single-center retrospective study examined a total of 220 patients diagnosed with limited-stage SCLC between January 2010 and June 2019. Bone marrow FDG uptake, serum inflammatory markers, and other factors used to determine the prognosis, as well as overall survival (OS) and progression-free survival (PFS), were recorded and retrospectively analyzed. Within physiological limits, bone marrow standardized uptake value (SUV) mean of > 1.95 was identified as a good prognostic factor for PFS (p= 0.03). The multivariate analysis of OS and PFS revealed that the Eastern Cooperative Oncology Group (ECOG) performance scale (p= 0.001) was a common independent prognostic factor. Stages of the disease, albumin levels and bone marrow-to-liver ratio (BLR) [one of the positron emission tomography/computed tomography (PET/CT) parameters] of < 0.8 were prognostic factors for OS. The bone marrow SUV mean was positively correlated with the primary tumor SUV max and SUV mean. The bone marrow SUV mean is a parameter that can be used to predict PFS in limited-stage SCLC. For OS, in turn, the BLR was identified as an independent factor.","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136369646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We sought to determine the predictive value of the systemic inflammation score (SIS) for radiation-induced trismus (RIT) and osteora-dionecrosis of the jaw (ORNJ) in locally advanced nasopharyngeal carcinoma (LA-NPC) patients treated with concurrent chemoradio-therapy (C-CRT). LA-NPC patients (n= 188) who underwent C-CRT and pre-and post-C-CRT oral examinations from August 2010 to January 2022 were included. The three-tiered SIS groups were created using the serum albumin and lymphocyte-to-monocyte ratio (LMR) measures obtained on the first day of C-CRT: SIS-0: Albumin ≥ 40 g/dL and LMR ≥ 4.44); SIS-1: Albumin < 40 g/dL and LMR < 4.44 or albumin ≥ 0 g/dL and LMR ≥ 4.44; and SIS-2: Albumin < 40 g/dL and LMR <4.44. The primary objective was to ascertain whether there were irrefutable associations between pretreatment SIS groups and the respective post-C-CRT RIT and ORNJ rates. RIT and ORNJ were diagnosed in 33 (17.6%) and 21 (11.1%) patients, respectively. There were 12 (32.4%), 13 (12.7%), and 18 (45.0%) cases diagnosed with RIT in the respective SIS-0, SIS-1, and SIS-2 groups (p< 0.001). Similarly, there were 1 (2.7%), 11 (9.9%), and 9 (22.5%) cases with ORNJ diagnoses in the corresponding SIS groups (p< 0.001). The multivariate analysis’s findings revealed that the SIS grouping was an independent predictor of RIT (p< 0.001) and ORNJ incidence rates (p< 0.001). Our study’s findings indicate that the novel pretreatment SIS grouping is a dependable biomarker-based system, which can accurately predict the rates of RIT and ORNJ in LA-NPC patients who receive definitive C-CRT.
{"title":"Systemic Inflammation Score for Predicting Radiation-Induced Trismus and Osteoradionecrosis of the Jaw Rates in Locally Advanced Nasopharyngeal Carcinoma Patients","authors":"Efsun Somay","doi":"10.4999/uhod.237293","DOIUrl":"https://doi.org/10.4999/uhod.237293","url":null,"abstract":"We sought to determine the predictive value of the systemic inflammation score (SIS) for radiation-induced trismus (RIT) and osteora-dionecrosis of the jaw (ORNJ) in locally advanced nasopharyngeal carcinoma (LA-NPC) patients treated with concurrent chemoradio-therapy (C-CRT). LA-NPC patients (n= 188) who underwent C-CRT and pre-and post-C-CRT oral examinations from August 2010 to January 2022 were included. The three-tiered SIS groups were created using the serum albumin and lymphocyte-to-monocyte ratio (LMR) measures obtained on the first day of C-CRT: SIS-0: Albumin ≥ 40 g/dL and LMR ≥ 4.44); SIS-1: Albumin < 40 g/dL and LMR < 4.44 or albumin ≥ 0 g/dL and LMR ≥ 4.44; and SIS-2: Albumin < 40 g/dL and LMR <4.44. The primary objective was to ascertain whether there were irrefutable associations between pretreatment SIS groups and the respective post-C-CRT RIT and ORNJ rates. RIT and ORNJ were diagnosed in 33 (17.6%) and 21 (11.1%) patients, respectively. There were 12 (32.4%), 13 (12.7%), and 18 (45.0%) cases diagnosed with RIT in the respective SIS-0, SIS-1, and SIS-2 groups (p< 0.001). Similarly, there were 1 (2.7%), 11 (9.9%), and 9 (22.5%) cases with ORNJ diagnoses in the corresponding SIS groups (p< 0.001). The multivariate analysis’s findings revealed that the SIS grouping was an independent predictor of RIT (p< 0.001) and ORNJ incidence rates (p< 0.001). Our study’s findings indicate that the novel pretreatment SIS grouping is a dependable biomarker-based system, which can accurately predict the rates of RIT and ORNJ in LA-NPC patients who receive definitive C-CRT.","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136369647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fatma YILMAZ1, Merih Reis ARAS1, Hacer Berna AFACAN OZTURK1, Umit Yavuz MALKAN2, Ayse Arslan KAPUCI3, Ahmet Kursad GUNES1, Murat ALBAYRAK1 1Ankara Etlik State Hospital, Department of Hematology, Ankara 2Hacettepe University Faculty of Medicine, Department of Hematology, Ankara 3Hacettepe University Faculty of Medicine, Department of Hematology, Ankara Keywords: GLIM criteria, Leukemias, Malnutrition, Recovery time Malnutrition is an important point in patients with hematological malignancies, especially in patients with leukemia who have the potential to enter into prolonged neutropenia. There is no generally accepted approach algorithm with a common consensus in determining the risk of malnutrition. The GLIM criteria, developed by a common consensus of major global nutrition societies (Global Leadership Initiative on Malnutrition), are one of the most frequently used approaches recently. Method A total of 50 patients with a diagnosis of leukemia (AML, ALL) were included in the study. NRS-2002 and then GLIM criteria were used to determine the nutritional status of the patients. The study parameters were evaluated by dividing the patients into two groups as malnourished and non-malnourished. Comparing the malnourished group to the non-malnourished group; while platelet, albumin, and prealbumin values and anthropometric measurements were found to be statistically significantly low, infection incidence rate, fever duration and rate, the need for multiple and longer courses of antibiotics and antifungal usage rate were found to be statistically significantly high (p< 0.005). Adequate nutritional level of the patient does not affect the neutrophil and platelet recovery time, but infection incidence rate and rate of fever within the same period of neutropenia statistically significantly reduces the need for antibiotics and antifungals. In patients with a diagnosis of leukemia who have long hospital stays, it is important to ensure adequate calorie intake with regular dietitian follow-up, to obtain a balanced calorie intake from macronutrients, and to add micronutrient support.
Fatma YILMAZ1, Merih Reis ARAS1, Hacer Berna AFACAN OZTURK1, Umit Yavuz MALKAN2, Ayse Arslan KAPUCI3, Ahmet Kursad GUNES1, Murat ALBAYRAK1安卡拉埃特利克国立医院血液科，安卡拉2Hacettepe大学医学院，血液科，安卡拉3Hacettepe大学医学院，血液科GLIM标准，白血病，营养不良，恢复时间营养不良是血液系统恶性肿瘤患者的一个重要方面，特别是白血病患者，有可能进入长期中性粒细胞减少。在确定营养不良风险方面，目前还没有一个普遍接受的方法和算法。GLIM标准是由全球主要营养学会(全球营养不良领导倡议)的共同共识制定的，是最近最常用的方法之一。方法对50例诊断为白血病(AML, ALL)的患者进行研究。采用NRS-2002和GLIM标准确定患者的营养状况。通过将患者分为营养不良和非营养不良两组来评估研究参数。比较营养不良组和非营养不良组;虽然血小板、白蛋白和白蛋白前值和人体测量值具有统计学意义低，但感染发生率、发烧持续时间和率、需要多疗程和更长疗程的抗生素和抗真菌药物使用率具有统计学意义高(p<0.005)。患者营养水平充足不影响中性粒细胞和血小板恢复时间，但中性粒细胞减少同期感染发生率和发热率有统计学意义地降低了对抗生素和抗真菌药物的需求。对于诊断为白血病且住院时间较长的患者，重要的是要确保足够的热量摄入，并定期进行营养师随访，从宏量营养素中获得平衡的热量摄入，并增加微量营养素的支持。
{"title":"The Relationship Between GLIM Criteria and Recovery Times in the Leukemia Treatment Process","authors":"Fatma Yilmaz","doi":"10.4999/uhod.237189","DOIUrl":"https://doi.org/10.4999/uhod.237189","url":null,"abstract":"Fatma YILMAZ1, Merih Reis ARAS1, Hacer Berna AFACAN OZTURK1, Umit Yavuz MALKAN2, Ayse Arslan KAPUCI3, Ahmet Kursad GUNES1, Murat ALBAYRAK1 1Ankara Etlik State Hospital, Department of Hematology, Ankara 2Hacettepe University Faculty of Medicine, Department of Hematology, Ankara 3Hacettepe University Faculty of Medicine, Department of Hematology, Ankara Keywords: GLIM criteria, Leukemias, Malnutrition, Recovery time Malnutrition is an important point in patients with hematological malignancies, especially in patients with leukemia who have the potential to enter into prolonged neutropenia. There is no generally accepted approach algorithm with a common consensus in determining the risk of malnutrition. The GLIM criteria, developed by a common consensus of major global nutrition societies (Global Leadership Initiative on Malnutrition), are one of the most frequently used approaches recently. Method A total of 50 patients with a diagnosis of leukemia (AML, ALL) were included in the study. NRS-2002 and then GLIM criteria were used to determine the nutritional status of the patients. The study parameters were evaluated by dividing the patients into two groups as malnourished and non-malnourished. Comparing the malnourished group to the non-malnourished group; while platelet, albumin, and prealbumin values and anthropometric measurements were found to be statistically significantly low, infection incidence rate, fever duration and rate, the need for multiple and longer courses of antibiotics and antifungal usage rate were found to be statistically significantly high (p< 0.005). Adequate nutritional level of the patient does not affect the neutrophil and platelet recovery time, but infection incidence rate and rate of fever within the same period of neutropenia statistically significantly reduces the need for antibiotics and antifungals. In patients with a diagnosis of leukemia who have long hospital stays, it is important to ensure adequate calorie intake with regular dietitian follow-up, to obtain a balanced calorie intake from macronutrients, and to add micronutrient support.","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"113 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136369827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Neutropenia and Low Infection Rates Dilemma of the CDK Inhibitors: A New Theory","authors":"AHMET ARDA UNAL","doi":"10.4999/uhod.237003","DOIUrl":"https://doi.org/10.4999/uhod.237003","url":null,"abstract":"","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135464093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Faruly Wijaya S. Limba, E. D. Yulian, D. Kartini, B. Andinata, H. Tjahjadi, D. Vidiawati
{"title":"Dickkopf-1 Expression as a Predicting Factor for Bone Metastasis in Breast Cancer","authors":"Faruly Wijaya S. Limba, E. D. Yulian, D. Kartini, B. Andinata, H. Tjahjadi, D. Vidiawati","doi":"10.4999/UHOD.204540","DOIUrl":"https://doi.org/10.4999/UHOD.204540","url":null,"abstract":"","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":"81 1","pages":"171-179"},"PeriodicalIF":0.6,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83390089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：